

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of  
Jean-Christophe LEROUX et al.

Application No.: 10/647,243

Filing Date: August 26, 2003

Title: COMPOSITION WITH GELLING  
PROPERTIES FOR THE SUSTAINED  
DELIVERY OF BIOACTIVE SUBSTANCES



Group Art Unit: 1653

Examiner: Marsha M. Tsay

Confirmation No.: 1768

SECOND  
INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a SECOND Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the fee due.
- ☐ Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

By

A handwritten signature in cursive script, reading "Mary Katherine Baumeister".

Mary Katherine Baumeister

Registration No. 26,254

Date: April 11, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Jean-Christophe LEROUX et al.

Application No.: 10/647,243

Filed: August 26, 2003

For: COMPOSITION WITH GELLING  
PROPERTIES FOR THE SUSTAINED  
DELIVERY OF BIOACTIVE  
SUBSTANCES

Group Art Unit: 1653

Examiner: Marsha M. Tsay

Confirmation No.: 1768

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of the document cited is enclosed. This document is a publication by the inventors and co-workers which occurred after the filing date of the present application. It is listed on the accompanying Form PTO-1449. This publication is not prior art and is cited simply to complete the record.

This Statement and its enclosures are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

It is respectfully requested that the Examiner consider this Statement and its enclosures and that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date April 11, 2005

By: Mary Katherine Baumeister  
Mary Katherine Baumeister  
Registration No. 26,254

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-662

# **SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number 10/647,243  
 Filing Date August 26, 2003  
 First Named Inventor Jean-Christophe LEROY  
 Examiner Name Marsha M. Tsay  
 Attorney Docket Number 017753-165

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Couffin-Hoarau et al., <i>Pharmaceutical Research</i> , Vol. 21, No. 3, March 2004, pp. 454-457, published by Plenum Publishers, New York, New York.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.